A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
Part of paid clinical trials in Cypress, California.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT05227196
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy Volunteers
- Type 2 Diabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Accepted
Interventions
- Semaglutide D Dose 1 — DRUGTablet given orally
- Semaglutide D Dose 2 — DRUGTablet given orally
- Semaglutide D Dose 3 — DRUGTablet given orally
- Semaglutide Dose 4 — DRUGTablet given orally
- Semaglutide Dose 5 — DRUGTablet given orally
- Semaglutide Dose 6 — DRUGTablet given orally
Study Details
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).
Key Dates
- First listed
- Feb 7, 2022
- Start date
- Feb 4, 2022
- Status verified
- Sep 2024
- Primary completion
- Jun 28, 2023
- Completion
- Aug 8, 2023
Study Design
- Enrollment
- 546 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1 Sequence 1Crossover arm
- Experimental: Group 1 Sequence 2Crossover arm
- Experimental: Group 2 Sequence 1Crossover arm
- Experimental: Group 2 Sequence 2Crossover arm
- Experimental: Group 3 Sequence 1Crossover arm
- Experimental: Group 3 Sequence 2Crossover arm
Primary Outcome Measure
AUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS) [ Time Frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154. ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Altasciences Clinical LA, Inc. | Cypress | California | 90630 | - |
| Altasciences Clinical Kansas, Inc. | Overland Park | Kansas | 66212 | - |
Find similar trials in Cypress, CA
Related Studies
- More Fresh Fruit and Vegetable Prescription Program for Families With Type 2 Diabetes MellitusRecruiting · University of California, San Diego · San Diego, California
- THC Effects on Glucose in Type 2 DiabetesPHASE1 · Recruiting · University of California, San Diego · La Jolla, California
- Latinos Understanding the Need for Adherence in Diabetes Using E-HealthRecruiting · San Diego State University · Chula Vista, California
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Los Angeles, California